Federal Register #2026-17991

Exclusive Patent License for Mifepristone and Analogues to Treat Insulin Resistance Disorders

This opportunity from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS), concerns an exclusive patent license for medical technology. - Government Buyer: - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - National Institutes of Health (NIH) - Department of Health and Human Services (HHS) - OEMs and Vendors: - Nulyn Science (prospective licensee) - Products/Services Requested: - Exclusive patent license for inventions related to mifepristone and analogues - Technology: Glucocorticoid receptor antagonists (e.g., mifepristone) for treating hypercortisolism-related insulin resistance disorders - Patent coverage includes: - Australian Patent Application No. 2020239920 - South Korean Patent Application No. 1020217033113 - New Zealand Patent Application No. 781109 - United States Patent Application Nos. 17/438,580 and 18/831,326 - European Patent 3941460 - Unique/Notable Requirements: - License is exclusive and limited to commercial development for the specified medical indication - Territory may be worldwide - No specific product purchases or quantities; this is for intellectual property rights - Focus is on treatment of hypercortisolism-related insulin resistance disorders in humans - No physical products or services are being procured; this is a licensing opportunity for patented technology.

Description

The National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to Nulyn Science for the development and commercialization of inventions related to mifepristone and its analogues. The technology involves a method for treating insulin sensitivity disorders by using glucocorticoid receptor antagonists to block metabolic side effects of cortisol. The license territory may be worldwide and is limited to commercial development for treating hypercortisolism-related insulin resistance disorders in humans. Comments and applications must be received by September 17, 2026.

View original listing